Editorial
Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?
Abstract
Risk factors of gestational diabetes mellitus (GDM) include overweight, hormonal changes, previous GDM, a family history of type 2 diabetes mellitus (T2DM), and polycystic ovarian syndrome (1,2). In approximately 90% of women, metabolic perturbations are transient (1,2). However, some women progress to T2DM post-partum, with ongoing endothelial inflammation, early atherosclerosis, increased coagulation, insulin resistance, central adiposity, metabolic syndrome (MetS), atherogenic dyslipidaemia and cardiovascular (CV) complications (3-7).